NCT00317200 - A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Small Cell Lung Cancer

Interventions

DRUG

Paclitaxel

Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.

DRUG

Bevacizumab

Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle

Trial Locations (17)

19046

Fox Chase Cancer Center Extramural Research Program, Rockledge

19106

Pennsylvania Oncology-Hematology Associates, Philadelphia

46202

Indiana University Cancer Center, Indianapolis

Quality Cancer Center (MCGOP), Indianapolis

46256

Community Regional Cancer Center, Indianapolis

46527

Center for Cancer Care at Goshen Health System, Goshen

46601

Northern Indiana Cancer Research Consortium, South Bend

46815

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

47150

Center for Cancer Care, Inc., P.C., New Albany

47303

Medical Consultants, P.C., Muncie

47403

Cancer Care Center of Southern Indiana, Bloomington

47714

Oncology Hematology Associates of SW Indiana, Evansville

47904

Arnett Cancer Care, Lafayette

61401

Medical & Surgical Specialists, LLC, Galesburg

63110

Siteman Cancer Center, St Louis

68114

Methodist Cancer Center, Omaha

72764

Highlands Oncology Group, Springdale